Sfoglia per Autore
Preliminary assessment of semiautomated segmentation tool for GBM neurosurgery: a BraTS-Toolkit approach
2024 Cerina, V; Rui, C; DE BERNARDI, E; Moresco, R; Giussani, C; Basso, G; DI CRISTOFORI, A
Molecular imaging of IDH-mutant gliomas in the new era of IDH inhibitors: preparing for future challenges
2024 Ninatti, G; Moresco, R; Sollini, M
A ROI-based quantitative pipeline for 18F-FDG PET metabolism and pCASL perfusion joint analysis: Validation of the 18F-FDG PET line
2024 Cerina, V; Crivellaro, C; Morzenti, S; Pozzi, F; Bigiogera, V; Jonghi-Lavarini, L; Moresco, R; Basso, G; De Bernardi, E
Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease
2024 Tassan Mazzocco, M; Serra, M; Maspero, M; Coliva, A; Presotto, L; Casu, M; Morelli, M; Moresco, R; Belloli, S; Pinna, A
New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia
2024 Zanardi, A; Nardini, I; Raia, S; Conti, A; Ferrini, B; D'Adamo, P; Gilberti, E; Depalma, G; Belloli, S; Monterisi, C; Coliva, A; Rainone, P; Moresco, R; Mori, F; Zurlo, G; Scali, C; Natali, L; Pancanti, A; Giovacchini, P; Magherini, G; Tovani, G; Salvini, L; Cicaloni, V; Tinti, C; Tinti, L; Lana, D; Magni, G; Giovannini, M; Gringeri, A; Caricasole, A; Alessio, M
Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method
2024 Iannone, M; Valtorta, S; Stucchi, S; Altomonte, S; Turolla, E; Vino, E; Rainone, P; Zecca, V; Lo Dico, A; Maspero, M; Figini, M; Bellone, M; Ciceri, S; Colombo, D; Chinello, C; Pagani, L; Moresco, R; Todde, S; Ferraboschi, P
Clinical applicability of pCASL as a substitute for FDG-PET in the etiological diagnosis of MCI and SCD: CAPE study protocol
2023 Pozzi, F; Cerina, V; Licciardo, D; Guo, W; Brambilla, A; Cosentino, G; Remoli, G; Da Re, F; Conti, E; Tremolizzo, L; Moresco, R; Isella, V; De Bernardi, E; Morzenti, S; Musarra, M; Crivellaro, C; Appollonio, I; Ferrarese, C; Basso, G
A ROI-based quantitative pipeline for 18F-FDG PET metabolism and pCASL perfusion joint analysis: validation on 18F-FDG PET data
2023 Cerina, V; DE BERNARDI, E; Crivellaro, C; Morzenti, S; Pozzi, F; Bigiogera, V; Jonghi-Lavarini, L; Moresco, R; Basso, G
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins
2023 Monieri, M; Rainone, P; Sacchi, A; Gori, A; Gasparri, A; Coliva, A; Citro, A; Ferrara, B; Policardi, M; Valtorta, S; Pocaterra, A; Alfano, M; Sheppard, D; Piemonti, L; Moresco, R; Corti, A; Curnis, F
Aberrant L-Fucose Accumulation and Increased Core Fucosylation Are Metabolic Liabilities in Mesenchymal Glioblastoma
2023 Pieri, V; Gallotti, A; Drago, D; Cominelli, M; Pagano, I; Conti, V; Valtorta, S; Coliva, A; Lago, S; Michelatti, D; Massimino, L; Ungaro, F; Perani, L; Spinelli, A; Castellano, A; Falini, A; Zippo, A; Poliani, P; Moresco, R; Andolfo, A; Galli, R
Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models
2023 Rainone, P; Valtorta, S; Villa, C; Todde, S; Cadamuro, M; Bertoli, G; Conconi, D; Lavitrano, M; Moresco, R
Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity
2023 Tassan Mazzocco, M; Murtaj, V; Martins, D; Schellino, R; Coliva, A; Toninelli, E; Vercelli, A; Turkheimer, F; Belloli, S; Moresco, R
The peritumoral brain zone in glioblastoma: where we are and where we are going
2023 Giambra, M; Di Cristofori, A; Valtorta, S; Manfrellotti, R; Bigiogera, V; Basso, G; Moresco, R; Giussani, C; Bentivegna, A
Modulazione del fenotipo cellulare indotto da radioterapia ipofrazionata in un modello murino di glioma
2023 Granata, S; Valtorta, S; Rainone, P; De Pretis, S; Diprima, S; Zerbetto, F; Villa, S; Di Muzio, N; Moresco, R
Application of reduction and refinement principles in the evaluation of prodromal markers of Parkinson’s disease in a progressive neurotoxic mouse model using multi-tracer PET imaging
2023 Tassan Mazzocco, M; Belloli, S; Pinna, A; Serra, M; Morelli, M; Moresco, R
Validation of brain 18FDG-PET and pCASL joint analysis tool: a ROI-based approach
2022 Cerina, V; De Bernardi, E; Bigiogera, V; Jonghi - Lavarini, L; Pozzi, F; Crivellaro, C; Morzenti, S; Apollonio, I; Ferrarese, C; Moresco, R; Basso, G
An optimized protocol for correlation of PET-FDG and pCASL data in mild cognitive impairment (MCI) patients
2022 Cerina, V; De Bernardi, E; Bigiogera, V; JONGHI - LAVARINI, L; Pozzi, F; Crivellaro, C; Morzenti, S; Moresco, R; Basso, G
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
2022 Novello, S; Mercatelli, D; Albanese, F; Domenicale, C; Brugnoli, A; D'Aversa, E; Vantaggiato, S; Dovero, S; Murtaj, V; Presotto, L; Borgatti, M; Shimshek, D; Bezard, E; Moresco, R; Belloli, S; Morari, M
Magnetic Resonance Imaging for neuronal degeneration evaluation in a Parkinson’s disease transgenic mouse model
2022 Magnino, S; Tassan Mazzocco, M; Parrella, E; Comelli, A; Stefano, A; Bellucci, A; Pizzi, M; Moresco, R; Belloli, S
PET imaging and single-cell RNA sequencing glioma microenvironment assessment after RT combined therapy
2022 Granata, S; Valtorta, S; Zerbetto, F; Todde, S; Iannone, M; Coliva, T; Spinelli, A; Bertoli, G; de Pretis, S; Diprima, S; Villa, S; DI MUZIO, N; Moresco, R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile